Overview :: IMV Inc. (IMV)

Corporate Presentation

May 29, 2020

Corporate Presentation

Upcoming Events

Jun 18, 2020 8:20 am EDT

Raymond James' Human Health Innovation Conference

Virtual

Past Events & Presentations

May 15, 2020 8:00 am EDT

First quarter 2020 Earnings and Clinical update Call

Apr 23, 2020 12:00 pm EDT

Adelaide Capital’s Virtual COVID & Healthcare Mini Conference

Mar 31, 2020 8:00 am EDT

Fourth Quarter 2019 Earnings Call

Feb 27, 2020 8:30 am EDT

Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac

Feb 25, 2020 8:00 am EDT

Conference Call & Webcast To Report Updated Results Of Phase 2 DeCidE1 Study

Feb 10, 2020 9:30 am EDT

BIO CEO 2020

Jan 13, 2020

JP Morgan Conference

View All Past Events

IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.

© 2020 IMV Inc. All rights reserved.

Clinical Trials

● Expanded Access

● Investigator-initiated Trials

Research & Development

Immuno-oncology

● Ovarian Cancer

Other Applications

● Infectious Diseases

Intellectual Property

Board of Directors

Company History

Business Development

Overview

Press Releases

Events, Webcasts & Presentations

Financial Info

Stock Data

Filings

Governance

Contact Us

FAQ

Life in Halifax

IMV Inc.

130 Eileen Stubbs Avenue, Suite 19
Dartmouth, Nova Scotia B3B 2C4

Tel: +1 902.492.1819

Fax: +1 902.492.0888

Québec Office
2875 Boulevard Laurier
Delta 1, Suite 220
Québec, Québec, Canada
G1V 2M2
Tel: +1 581.741.0519

© 2020 IMV Inc. All rights reserved.